Discounted Cash Flow (DCF) Analysis Levered

NeuBase Therapeutics, Inc. (NBSE)

$0.18

-0.00 (-1.37%)
Financial Summary
Financial Statements
Quarter Financials
Chart
Financial Ratios
Profile
Historical Data
DCFDCF Levered
All numbers are in Millions, Currency in USD

Free Cash Flow

Year
A/P
2018
Projected
2019
Projected
2020
Projected
2021
Projected
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
2027
Projected
Revenue ----------
Revenue (%)
Operating Cash Flow ----------
Operating Cash Flow (%)
Capital Expenditure ----------
Capital Expenditure (%)
Free Cash Flow ----------

Weighted Average Cost Of Capital

Share price $ 0.18
Beta 0.851
Diluted Shares Outstanding 32.49
Cost of Debt
Tax Rate 0.00
After-tax Cost of Debt 0.40%
Risk-Free Rate
Market Risk Premium
Cost of Equity 7.717
Total Debt 6
Total Equity 5.85
Total Capital 11.84
Debt Weighting 50.63
Equity Weighting 49.37
Wacc

Build Up Free Cash Flow

Year
A/P
2018
Projected
2019
Projected
2020
Projected
2021
Projected
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
2027
Projected
Revenue ----------
Operating Cash Flow ----------
Capital Expenditure ----------
Free Cash Flow ----------
WACC
PV LFCF ----------
SUM PV LFCF -

Terminal Value

Growth in perpetuity method:
Long-term growth rate
WACC (%) 4.01
Free cash flow (t + 1) -
Terminal Value -
Present Value of Terminal Value -

Intrinsic Value

Enterprise Value -
Net Debt -17.16
Equity Value -
Shares Outstanding 32.49
Equity Value Per Share -